The nitroreductase (NR)/CB1954 enzyme prodrug system has given promising results in pre-clinical studies and is currently being assessed in phase I and II clinical trials in prostate cancer. Enhanced cell killing by apparent immune-mediated mechanisms has been shown in pancreatic and colorectal cancer models, by co-expressing murine granulocyte macrophage colony-stimulating factor (GM-CSF) with NR in a single replication deficient adenoviral vector. This consists of the CMV immediate early promotor driving expression of NR, with an internal ribosome entry site (IRES) and the gene for murine GM-CSF (mGM-CSF). To examine if similar enhancement of tumour cell killing could be produced in prostate cancer, the TRAMP model was chosen. Results illustrate that the combination of suicide gene therapy using NR and CB1954, with cytokine stimulation with mGM-CSF gives an improved response compared with either modality alone. The mechanism of this improved response is however likely to be non-immune based as it lacks a memory effect.
Introduction
Virus dependent enzyme prodrug therapy is an attractive candidate for future localized therapy of prostate cancer. The prodrug 5-(aziridin-1-yl)-2, 4 dinitrobenzamide or CB1954 are converted by the gene Escherichia coli nitroreductase (NR) into 2-and 4-hydroxylamino derivatives. The 4-hydroxylamino derivative is subsequently converted by cellular thioesters into a potent cytotoxic bifunctional alkylating agent capable of crosslinking DNA.
1 Activated CB1954 acts as an alkylating agent and appears to be cell-cycle independent.
2 This is a significant potential advantage, particularly in slower growing tumours such as prostate cancer, where a minority of cells is likely to be dividing at any one time. The principal disadvantages of this system are the relative toxicity of CB1954 in humans, 3 although it is extremely well tolerated via the intraperitoneal route, and the relatively poor catalytic efficiency of NR for CB1954.
This system has been assessed in vitro and in vivo in both retroviral 4 and adenoviral vectors. 5 Clinical trials of NR expressing adenoviral vectors with CB1954 have been carried out in liver, 6 head and neck and prostate cancer. Whilst this system might offer effective treatment for localized tumours, the prospect of utilizing the body's own immune response to enhance local and add systemic response to cancer cells is obviously attractive. It could provide specificity not hitherto achieved in cancer therapy as well as possible life-long surveillance for recurrence. Many approaches have been tried to elicit such responses in prostate cancer, including the use of BCG, 7 tumour vaccines, 8 ex vivo dendritic cell-based approaches, 9 bi-specific antibodies 10 and GM-CSF. 11 Autoimmunity is a hallmark of successful breakdown of immune tolerance necessary for cancer immunotherapy, 12 and this would be unlikely to be a significant clinical problem in prostate cancer, compared with most solid tumours, as the prostate is inessential after reproduction.
GM-CSF plays a key role in promoting anti-tumour immune responses, 13 and indeed reports comparing the ability of different cytokines to enhance the immunogenicity of murine tumour cells have shown that GM-CSF secreting tumour cells stimulated potent, specific and long-lasting anti-tumour immunity.
14,15 A recombinant fusion protein containing prostatic acid phosphatase and GM-CSF has been used successfully to prime autologous antigen presenting cells. 16 There is increasing evidence that cellular stress responses, such as may be induced by viral cell infection, are necessary to elicit an immune response. [17] [18] [19] [20] [21] Furthermore, adenoviral vectors encoding bicistronic HSV-TK and GM-CSF were effective in generating an anti-tumour immune response. 18, 23 Co-expression of high levels of the stress response protein heat protein 70 enhanced antitumour effects in vivo. 24, 25 Previous data from work in our group suggested that cell killing by CB1954 provoked a systemic immune response, in a mouse mesothelioma model: in AB22 mice bearing murine mesothelioma tumours that stably express NR, some tumours failed to grow after treatment with CB1954, and the surviving animals were protected from a subsequent rechallenge with unmodified AB22 cells. 26 To examine these effects further and their potential enhancement by cytokines, an adenovirus vector containing CMV-NR, a picornavirus internal ribosome entry site (IRES) and the gene for murine GM-CSF (mGM-CSF) has been constructed. 26 This vector has greater therapeutic efficacy in the MC26 murine colorectal tumour model, compared with viruses expressing only one of the transgenes.
Historically, prostate cancer was not thought to be responsive to immunotherapy, although more recently many immunotherapeutic approaches have been attempted, including the use of cytokines to induce antitumour responses. Critical examination of the literature suggests evidence that GM-CSF may have a direct effect against prostate cancer rather than necessarily an immune-mediated effect. 27 PSA responses to administration were more rapid than might be expected from a generated immune response. Furthermore, IL-12, but not GMCSF was found to enhance killing of TRAMP C2 cells using an oncolytic herpes simplex virus to deliver transgene, 28 so the position of GMCSF as a key immunebased molecule in prostate cancer was far from clear. The role of GMCSF in a VDEPT model was therefore examined to find if additional anti-tumour effects could be generated. If GMCSF increased cancer cell killing it was also necessary to see if long-term anti-tumour immune memory was generated, or if GMCSF acted via other means.
As an in vivo model, the TRAMP cell lines C1, C2 and C3 are well characterized. [29] [30] [31] TRAMP is a transgenic line of C57BL/6 mice that develop histological prostatic intraepithelial neoplasia by 8-12 weeks of age and progress to invasive adenocarcinoma with metastasis by 24-30 weeks of age. The TRAMP model was established using the À426/ þ 28 rat probasin promoter to target expression of the simian virus 40 large T antigen to prostatic epithelium. From this model, three cell lines were established. These were designated TRAMP-C1, C2 and C3. Cell lines C1 and C2 are tumourigenic when grafted into syngeneic C57BL/6 hosts. This offers an immunocompetent model of prostate cancer that facilitates therapeutic access, necessary in VDEPT models. In this model humane end points are reached around 54 days after seeding in controls. Injection of established subcutaneous C2 tumours could not be used, as tumours were highly variable in size and form when large enough for injection reached humane end points too rapidly to establish therapeutic efficacy; therefore an ex vivo method was used to infect uniform numbers of cells at constant multiplicity of infection. The subsequent development of tumours was then used to study the effects of NR/CB1954 and mouse GMCSF in an immunocompetent prostate cancer model.
Materials and methods

Cell culture
TRAMP cell lines were obtained from Baylor College of Medicine, Texas Medical Centre, Houston, TX, USA. A total of 911 cells used for virus propagation were a gift from Prof R Hoeben, Leiden University, The Netherlands.
Cells were grown in their recommended media. CB1954 was obtained from ML Laboratories (currently Innovata PLC, Nottingham, UK).
Generation of replication defective adenoviral vectors
Replication defective E1A deleted adenoviruses encoding the transgenes NR, mGM-CSF and NR/mGM-CSF were constructed as previously described. 20 Recombinant replication defective viruses were subjected to two rounds of plaque purification and subjected to four rounds of amplification on 911 cells (p4 stocks). The titre of viral stocks was determined by plaque assay on 911 cells under agar.
Immunocytochemistry for nitroreductase
TRAMP C2 cells were infected in vitro with the bicistronic suicide gene/immunotherapy vector Ad5-CMV-NR/mGM-CSF to assess expression levels of the therapeutic transgene NR. A total of 50 000 cells per well seeded in 24-well plates were infected at varying multiplicities of infection (MOI) and the cells fixed at 48 h post-infection with 3% formaldehyde. This time point, just before peak transgene expression, was chosen as cells tended to become over confluent by 72 h postinfection, and have poor adherence to culture media during the process of immunocytochemistry. Immunocytochemistry was then performed for NR expression using a polyclonal sheep anti-NR antibody with an HRPconjugated rabbit anti-sheep secondary antibody using the Vecta ABC Horseradish peroxidase staining kit.
Cytotoxicity assays
For assessing CB1954-mediated toxicity, approximately 5-10 000 cells per well were seeded into 96-well plates in a volume of 200 ml per well, before infection with the appropriate adenoviral gene therapy vector at varying MOI. After 72 h of infection, prodrug CB1954 was added in varying concentrations for a further 72 h until 40 ml CellTiter 96 reagent (Promega UK, Southampton, UK) was added, the plate incubated at 37 1C for a further hour and read at 570 nm in a Wallac Victor 2 1420 Multilabel Counter and non-specific absorbance was subtracted from the values obtained by also reading optical density at 700 nm.
Animal models
Syngeneic murine tumours were grown in male C57/Bl6 mice obtained from the Biomedical Services Unit, University of Birmingham. After implantation of 5 Â 10 6 cells, mice were maintained in microisolator cages equipped with filter tops. All mice were pathogen free and weighed over 20 g at the commencement of experimental procedures. Procedures were in accordance with the appropriate national guidelines and were performed with the authority of Home Office Project and Personal Licences. ) or vehicle (PBS) by intraperitoneal injection on the subsequent 4 days. Tumours were visible approximately 4-6 weeks after implantation; animals were monitored daily and tumour sizes measured weekly using Vernier calipers. In accordance with national recommendations, animals were culled when tumour sizes reached 12 mm in diameter (which was significantly less than 10% of total body mass), if there were signs of imminent tumour ulceration, or if animals showed any signs of illness or lost 415% of their starting body weight.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 3 package; survival data was presented as KaplanMeier curves and the differences between curves were analysed using the Mantel-Haenszel log rank test. Infectivity and expression of both NR and mGM-CSF were further assessed using Ad5-CMV-NR/mGM-CSF infecting TRAMP C2 cells in vitro. Cells were infected at varying MOI from 0 to 300 PFU per cell (Figure 1 ) and expression levels assessed by immunocytochemistry 48 h post-infection.
Results
Infectivity
As expected, an increasing number of cells stained positively for NR expression with increasing MOI. 21 This difference seems to arise due to less efficient translation of the second message in the dual mRNA at the IRES compared with the first. Levels of mGM-CSF secreted from Ad5-CMV-mGM-CSF were higher than previously reported from stably transfected cell lines (13-130 ng ml À1 per 10 6 cells per 48 h). 32 Even at the lowest MOI (50) of Ad5-CMV-mGM-CSF, around 200 ng ml À1 per 48 h per 10 6 cells was secreted into the medium, and this increased at higher MOIs (Figure 2 ). This may be attributed to the powerful CMV IE promoter utilized in our experiments.
Enhancement of toxicity to CB1954 by NR encoding adenoviruses in vitro
A total of 3000 TRAMP C2 cells per well were seeded in a 96-well plate and infected at varying MOI with Ad5-CMV-NR or Ad5-CMV-NR/mGM-CSF. At 72 h postinfection, CB1954 was added at varying concentration. After a further 72 h, cytotoxicity was assessed with the Celltiter 96 assay. The results are shown in Figures 3a and b. There was no statistically significant difference in vitro between the Ad5-CMV-NR and the Ad5-CMV-NR/ mGM-CSF viruses in their enhancement of toxicity to CB1954, or toxicity produced by virus alone. Given that a minority of tumour cells are probably transduced to express NR even at high MOI, cell killing was remarkably effective and suggests that in this model a bystander effect is pronounced as has previously been well described in the NR/CB1954 system. 33 As there is evidence that GM-CSF may have a direct effect against prostate cancer, 22 a separate experiment to assess direct toxicity effects of mGM-CSF on TRAMP C2 cells in vitro was performed. TRAMP C2 cells were infected at varying MOI with Ad5-CMV-mGM-CSF, as this vector had been shown to produce approximately 5-fold greater concentrations of mGM-CSF compared with Ad5-CMV-NR/mGM-CSF. A total of 3000 cells per well were seeded into a 96-well plate and infected. Six days post-infection cytotoxicity was assessed with the Celltiter 96 assay. The result is shown in Figure 4 . Minimal toxicity was produced at MOIs up to 30 PFU per cell, but at 100 PFU per cell 20.5% cells produced were killed. This was similar to direct virus toxicity from previous cytotoxicity experiments with Ad5-CMV-NR and Ad5-CMV-NR/mGM-CSF in cells treated with virus only (and CB1954 not added). This suggested that mGM-CSF by itself produced minimal toxicity in vitro directly on TRAMP C2 cells.
Survival of C57/BL6 mice and tumour growth following ex vivo gene therapy of TRAMP C2 tumours treated with Ad5-CMV-NR/mGM-CSF, Ad5-CMV-mGM-CSF or Ad5-CMV-NR TRAMP C2 cells were infected with either Ad5-CMV-NR/mGM-CSF, Ad5-CMV-mGM-CSF or Ad5-CMV-NR in vitro at an MOI of 100. A further control group of cells was uninfected. Cells were harvested after 24 h, washed, resuspended in PBS and 5 Â 10 6 cells in 200 ml PBS were injected into the right flank of a shaved C57/Bl6 male mouse. Each experimental group contained eight animals. After seeding, mice in experimental groups were administered 20 mg kg À1 CB1954 or vehicle (PBS) by intraperitoneal injection daily for 4 days, starting at 24 h post-tumour seeding. Figures 5a and b show the subsequent tumour growth, and the time for the tumours to reach the humane end point specified in Materials and Methods (for ease of description, this is referred to henceforth as 'survival').
Tumour development and growth were most delayed by treatment ex vivo with NR expressing viruses followed by intraperitoneal CB1954. Only one animal developed a tumour in the Ad5-CMV-NR/mGM-CSF þ CB1954 group and this did not appear until day 63 postimplantation, compared with the vehicle þ vehicle control group, where tumours appeared from day 28. In terms of survival, differences between groups were even more marked. Survival was best in the Ad5-CMV-NR/ Survival of mice infected with Ad5-CMV-NR/mGM-CSF þ CB1954 was superior to those treated with Ad5-CMV-NR þ CB1954 (P ¼ 0.007). Enhancement of toxicity to CB1954 generated in vitro differed little between dual NR/mGM-CSF and single NR expressing vectors (Figures 3a and b) . Furthermore, no evidence of direct toxicity of mGM-CSF produced from adenovirus vectors was found in vitro (Figure 4) . It was initially thought therefore that the observed superiority of the dual vector in vivo might be due to enhancement of host immunity rather than direct effects of mGM-CSF on the growth of TRAMP cells.
We noted the necessity of NR in addition to mGM-CSF to enhance anti-tumour effects. We speculated that this might be due to the necessity for cell killing or appropriate stress signals to help elicit an immune response. It might also have been due to reduction in tumour mass by NR/CB1954, 'buying time' for an antitumour response to be generated. Prostatic epithelial cells are known to exist in an environment where their growth is greatly controlled by paracrine factors, and it is likely that early cancers' growth is still strongly influenced by locally produced growth factors. 34 GMCSF might act therefore indirectly in vivo via influencing prostatic interstitial cells and their release of paracrine factors that influence the growth/apoptosis balance.
Rechallenge of long-term survivors from the Ad5-CMV-NR/mGM-CSF þ CB1954 group
In order to ascertain whether the long-term survivors of the previous experiment in the Ad5-CMV-NR/mGM-CSF þ CB1954 treated group had developed long-term immunity to TRAMP C2 cells they were injected on the contralateral flank with 5 Â 10 6 TRAMP C2 cells. Naïve, unchallenged mice were similarly injected as a control for tumourigenicity of cells injected. This was performed on day 114 after the initial injections of TRAMP C2 cells with varying treatments. Subsequent growth of tumours and animal survival are illustrated in Figures 6a and b, respectively. There was no significant difference in growth between naïve and previously challenged mice suggesting that the therapeutic effect of the dually expressing mGM-CSF and NR virus in combination with CB1954 did not confer a long-term immune benefit. Two animals in the long-term survivor group developed bilateral flank tumours very late in the experiment (day 170 post-initial injection; day 56 post-rechallenge) indicating that cells initially injected had formed very slow growing tumours, or possibly that immune mechanisms were slowly overwhelmed before tumour growth could occur. . Subcutaneous seeding of TRAMP C2 cells was performed following infection with Ad5-CMV-NR/mGM-CSF, (indicated as 'Ad5-NR/mGM-CSF') Ad5-CMV-NR, Ad5-CMVmGM-CSF (indicated as 'Ad5-mGM-CSF') or vehicle (PBS). This was followed by four consecutive daily doses of 20 mg kg À1 CB1954 (indicated as 'CB') or vehicle. Cells were allowed to grow to form tumours until end points were reached in accordance with national guidelines. Host animal survival is illustrated.
Therapy for prostate cancer JG Young et al Similarly, there was no significant difference in median survival in the rechallenge group-69 days post-rechallenge versus 60 days in the naïve group (P ¼ 0.67).
Discussion
In vitro experiments in the TRAMP C2 model confirmed the cells' infectivity with human replication deficient adenoviruses and expression of transgenes driven from a CMV IE promoter. Further in vitro experiments showed enhancement of toxicity to the prodrug CB1954 following infection with NR expressing adenovirus vectors. Mouse GMCSF did not have a directly toxic effect on TRAMP C2 cells in vitro. However, in vivo, co-expression of NR and mGMCSF and administration of CB1954 was able to cure 7/8 animals of their TRAMP C2 tumours for the initial duration of the experiment (125 days). Animals treated without mGMCSF gained clinically and statistically significant tumour growth inhibition and survival benefit from ex vivo treatment of cancer cells with NR expressing vectors and administration of CB1954. This, however, generally only prolonged survival and did not prevent eventual tumour growth reaching experimental end points.
In order to ascertain the mechanism of this improvement in tumour growth and survival with mGMCSF a second rechallenge experiment was performed in vivo, with long-term survivors generated from the initial experiment readministered TRAMP C2 cells on their opposite flank. No long-term tumour growth inhibition or survival advantage was conferred on these animals by their previous exposure to mGMCSF and NR expressing vectors with CB1954 and their subsequent initial survival from tumour inoculation. This does not support the proposition that mGMCSF acts via enhancement or generation of host-specific immunity to C2 tumour cells. Mouse GMCSF seems likely to act either through nonspecific inflammatory mechanisms or possibly via influencing prostatic interstitial cells' release of paracrine factors known to influence the growth of epithelial cells. Whilst the possible therapeutic combination of NR/ CB1954 and mGM-CSF seems promising, this must be tempered by much remaining to be elucidated on this clear enhancing effect of NR/CB1954 and mGM-CSF in prostate cancer. Therapy for prostate cancer JG Young et al
